Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation

Cardiovascular Research

Volumn 89, Issue 4, 2011, Pages 754-765

  De Jong, Anne Margreet ^a,b   Maass, Alexander H ^a   Oberdorf Maass, Silke U ^a   Van Veldhuisen, Dirk J ^a   Van Gilst, Wiek H ^a,b   Van Gelder, Isabelle C ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Atrial fibrillation; Atrium; Remodelling; Stretch

Indexed keywords

CALCINEURIN; ENDOTHELIN 1; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; NATRIURETIC FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; CELL DEDIFFERENTIATION; DOWNSTREAM PROCESSING; FIBROSIS; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; MECHANICAL STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHABDOMYOLYSIS; SINUS RHYTHM;

ANIMALS; APOPTOSIS; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; CELL DIFFERENTIATION; FIBROSIS; HEART ATRIA; HUMANS; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

EID: 79951893447     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq357     Document Type: Review

References (135)

1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-953.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114: 119-125.
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
4. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92: 1954-1968.
5. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96:3157-3163. (Pubitemid 27500121)
6. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73.
7. Ho SY, Anderson RH, Sanchez-Quintana D. Atrial structure and fibres: morphologic bases of atrial conduction. Cardiovasc Res 2002;54:325-336. (Pubitemid 34327912)
8. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
9. Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005;67:655-666. (Pubitemid 41033361)
10. Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003;108:1461-1468. (Pubitemid 37176452)
11. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995;25:1155-1160.
12. Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008;10:21-27. (Pubitemid 351767271)
13. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95. (Pubitemid 29297945)
14. Schoonderwoerd BA, Ausma J, Crijns HJ, Van Veldhuisen DJ, Blaauw EH, Van Gelder IC. Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol 2004;15:1167-1174. (Pubitemid 39429501)
15. Anne W, Willems R, Holemans P, Beckers F, Roskams T, Lenaerts I et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007;43:148-158. (Pubitemid 47069383)
16. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-1595.
17. Everett TH, Li H, Mangrum JM, McRury ID, Mitchell MA, Redick JA et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000;102:1454-1460.
18. Bauer A, McDonald AD, Donahue JK. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 2004;61: 764-770. (Pubitemid 38249475)
19. Moe GW, Laurent G, Doumanovskaia L, Konig A, Hu X, Dorian P. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. J Card Fail 2008;14:768-776.
20. Shimano M, Tsuji Y, Inden Y, Kitamura K, Uchikawa T, Harata S et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008;5:451-459.
21. Kistler PM, Sanders P, Dodic M, Spence SJ, Samuel CS, Zhao C et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006;27:3045-3056. (Pubitemid 44950450)
22. Lau DH, Mackenzie L, Kelly DJ, Psaltis PJ, Brooks AG, Worthington M et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm 2010;7:1282-1290.
23. Remes J, van Brakel TJ, Bolotin G, Garber C, de Jong MM, van der Veen FH et al. Persistent atrial fibrillation in a goat model of chronic left atrial overload. J Thorac Cardiovasc Surg 2008;136:1005-1011.
24. Deroubaix E, Folliguet T, Rucker-Martin C, Dinanian S, Boixel C, Validire P et al. Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electrophysiologic abnormalities and atrial vulnerability. J Am Coll Cardiol 2004; 44:1918-1926. (Pubitemid 39424096)
25. Verheule S, Wilson E, Everett T, Shanbhag S, Golden C, Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003;107:2615-2622. (Pubitemid 36628945)
26. Boyden PA, Tilley LP, Pham TD, Liu SK, Fenoglic JJ Jr, Wit AL. Effects of left atrial enlargement on atrial transmembrane potentials and structure in dogs with mitral valve fibrosis. Am J Cardiol 1982;49:1896-1908. (Pubitemid 12059045)
27. Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010;120:242-253.
28. Boyden PA, Tilley LP, Albala A, Liu SK, Fenoglio JJ Jr, Wit AL. Mechanisms for atrial arrhythmias associated with cardiomyopathy: a study of feline hearts with primary myocardial disease. Circulation 1984;69:1036-1047. (Pubitemid 14137300)
29. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-1184. (Pubitemid 27344221)
30. Thiedemann KU, Ferrans VJ. Left atrial ultrastructure in mitral valvular disease. Am J Pathol 1977;89:575-604. (Pubitemid 8254188)
31. Han W, Fu S, Wei N, Xie B, Li W, Yang S et al. Nitric oxide overproduction derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. Int J Cardiol 2008;130:165-173.
32. Eiras S, Narolska NA, van Loon RB, Boontje NM, Zaremba R, Jimenez CR et al. Alterations in contractile protein composition and function in human atrial dilatation and atrial fibrillation. J Mol Cell Cardiol 2006;41:467-477. (Pubitemid 44344292)
33. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34:1577-1586. (Pubitemid 29528674)
34. Rucker-Martin C, Pecker F, Godreau D, Hatem SN. Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro. Cardiovasc Res 2002;55:38-52. (Pubitemid 34615938)
35. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008;12:189-208.
36. Ke L, Qi XY, Dijkhuis AJ, Chartier D, Nattel S, Henning RH et al. Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. J Mol Cell Cardiol 2008;45:685-693.
37. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
38. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J 2006;152:420-426. (Pubitemid 44233429)
39. Smit MD, Van Gelder IC. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther 2009;7:763-778.
40. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010;375:1212-1223.
41. Ausma J, Litjens N, Lenders MH, Duimel H, Mast F, Wouters L et al. Time course of atrial fibrillation-induced cellular structural remodeling in atria of the goat. J Mol Cell Cardiol 2001;33:2083-2094. (Pubitemid 34073052)
42. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990;82:792-797.
43. Ausma J, Borgers M. Dedifferentiation of atrial cardiomyocytes: from in vivo to in vitro. Cardiovasc Res 2002;55:9-12. (Pubitemid 34615935)
44. Barth AS, Merk S, Arnoldi E, Zwermann L, Kloos P, Gebauer M et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 2005;96:1022-1029.
45. Pikkarainen S, Tokola H, Majalahti-Palviainen T, Kerkela R, Hautala N, Bhalla SS et al. GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. J Biol Chem 2003;278:23807-23816. (Pubitemid 36830205)
46. Ausma J, Wijffels M, van Eys G, Koide M, Ramaekers F, Allessie M et al. Dedifferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation. Am J Pathol 1997; 151:985-997. (Pubitemid 27424308)
47. Avitall B, Bi J, Mykytsey A, Chicos A. Atrial and ventricular fibrosis induced by atrial fibrillation: evidence to support early rhythm control. Heart Rhythm 2008;5: 839-845.
48. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-776.
49. Dispersyn GD, Ausma J, Thone F, Flameng W, Vanoverschelde JL, Allessie MA et al. Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. Cardiovasc Res 1999;43:947-957. (Pubitemid 29413194)
50. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003;60:315-325. (Pubitemid 37412365)
51. Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001;103:691-698. (Pubitemid 32144198)
52. Nazir SA, Lab MJ. Mechanoelectric feedback in the atrium of the isolated guinea-pig heart. Cardiovasc Res 1996;32:112-119. (Pubitemid 26232658)
53. Bode F, Katchman A, Woosley RL, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation 2000;101:2200-2205. (Pubitemid 30253050)
54. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996;7: 833-842. (Pubitemid 26307704)
55. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001;89:453-460. (Pubitemid 34132662)
56. Rana OR, Zobel C, Saygili E, Brixius K, Gramley F, Schimpf T et al. A simple device to apply equibiaxial strain to cells cultured on flexible membranes. Am J Physiol Heart Circ Physiol 2008;294:H532-H540.
57. De Jong AR, Maass AH, Oberdorf-Maass SU, De Boer RA, Van Gilst WH, Van Gelder IC. Cell culture model for structural changes occurring before onset of atrial fibrillation. Circulation 2009;120:S712. (Abstract).
58. Saygili E, Rana OR, Meyer C, Gemein C, Andrzejewski MG, Ludwig A et al. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes. Basic Res Cardiol 2009;104: 435-448.
59. Saygili E, Rana OR, Saygili E, Reuter H, Frank K, Schwinger RH et al. Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. Am J Physiol Heart Circ Physiol 2007;292:H2898-H2905. (Pubitemid 47084539)
60. Brundel BJ, Van Gelder IC, Henning RH, Tuinenburg AE, Deelman LE, Tieleman RG et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res 1999;42:443-454. (Pubitemid 29243170)
61. Van Gelder IC, Brundel BJ, Henning RH, Tuinenburg AE, Tieleman RG, Deelman L et al. Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:552-560. (Pubitemid 29215336)
62. 2+ currents and human atrial fibrillation. Circ Res 1999;85:428-436.
63. Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 2008;52:293-299.
64. Ruwhof C, van Wamel JT, Noordzij LA, Aydin S, Harper JC, van der Laarse A. Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal rat cardiomyocytes. Cell Calcium 2001;29:73-83. (Pubitemid 32156828)
65. Liao XD, Tang AH, Chen Q, Jin HJ, Wu CH, Chen LY et al. Role of Ca2+ signaling in initiation of stretch-induced apoptosis in neonatal heart cells. Biochem Biophys Res Commun 2003;310:405-411. (Pubitemid 37163679)
66. Zobel C, Rana OR, Saygili E, Bolck B, Saygili E, Diedrichs H et al. Mechanisms of Ca2+-dependent calcineurin activation in mechanical stretch-induced hypertrophy. Cardiology 2007;107:281-290. (Pubitemid 46788245)
67. Kamkin A, Kiseleva I, Wagner KD, Bohm J, Theres H, Gunther J et al. Characterization of stretch-activated ion currents in isolated atrial myocytes from human hearts. Pflugers Arch 2003;446:339-346. (Pubitemid 36791739)
68. Le Grand BL, Hatem S, Deroubaix E, Couetil JP, Coraboeuf E. Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 1994;28: 548-556. (Pubitemid 24146181)
69. Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation 1996;93:1747-1754. (Pubitemid 26131353)
70. Tieleman RG, De Langen C, Van Gelder IC, de Kam PJ, Grandjean J, Bel KJ et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997;95:1945-1953. (Pubitemid 27164414)
71. Zarse M, Stellbrink C, Athanatou E, Robert J, Schotten U, Hanrath P. Verapamil prevents stretch-induced shortening of atrial effective refractory period in langendorff-perfused rabbit heart. J Cardiovasc Electrophysiol 2001;12:85-92. (Pubitemid 32099489)
72. Tieleman RG, Blaauw Y, Van Gelder IC, De Langen CD, de Kam PJ, Grandjean JG et al. Digoxin delays recovery from tachycardia-induced electrical remodeling of the atria. Circulation 1999;100:1836-1842. (Pubitemid 29498392)
73. Okamura K, Ito M, Tanaka K, Chinushi M, Adachi T, Mitsuma W et al. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats. Pharmacology 2009;83:360-366.
74. Van Noord T, Van Gelder IC, Tieleman RG, Bosker HA, Tuinenburg AE, Volkers C et al. VERDICT: the Verapamil versus Digoxin Cardioversion Trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2001;12:766-769. (Pubitemid 32607255)
75. Hemels ME, Van Noord T, Crijns HJ, Van Veldhuisen DJ, Veeger NJ, Bosker HA et al. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol 2006;48:1001-1009. (Pubitemid 44382682)
76. Bukowska A, Lendeckel U, Hirte D,Wolke C, Striggow F, Rohnert P et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci 2006;63:333-342. (Pubitemid 43202314)
77. Lin CC, Lin JL, Lin CS, Tsai MC, Su MJ, Lai LP et al. Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation. Chest 2004;126:1926-1932.
78. Qi XY, Yeh YH, Xiao L, Burstein B, Maguy A, Chartier D et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res 2008; 103:845-854.
79. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 2000; 87:731-738.
80. Frey N, Richardson JA, Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci U S A 2000;97:14632-14637. (Pubitemid 32016627)
81. Buch MH, Pickard A, Rodriguez A, Gillies S, Maass AH, Emerson M et al. The sarcolemmal calcium pump inhibits the calcineurin/nuclear factor of activated T-cell pathway via interaction with the calcineurin A catalytic subunit. J Biol Chem 2005; 280:29479-29487. (Pubitemid 41177021)
82. Heineke J, Ruetten H, Willenbockel C, Gross SC, Naguib M, Schaefer A et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci USA 2005; 102:1655-1660. (Pubitemid 40209223)
83. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006;69:865-875. (Pubitemid 43227985)
84. Greiser M, Neuberger HR, Harks E, El-Armouche A, Boknik P, de Haan S.et al. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol 2009;46:385-394.
85. 2+ leak promotes atrial fibrillation in mice. J Clin Invest 2009;119:1940-1951.
86. Brundel BJ, Ausma J, Van Gelder IC, Van der Want JJ, Van Gilst WH, Crijns HJ et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 2002;54:380-389. (Pubitemid 34327916)
87. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678-2681.
88. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677. (Pubitemid 30307515)
89. Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008;117:344-355.
90. Liang F, Gardner DG. Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes. J Biol Chem 1998;273:14612-14619. (Pubitemid 28319186)
91. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004;6:499-506. (Pubitemid 38786592)
92. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839. (Pubitemid 40789940)
93. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-1617.
94. Tuinenburg AE, Van Veldhuisen DJ, Boomsma F, Van den Berg MP, de Kam PJ, Crijns HJ. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol 1998;81:1207-1210.
95. Brundel BJ, Van Gelder IC, Tuinenburg AE, Wietses M, Van Veldhuisen DJ, Van Gilst WH et al. Endothelin system in human persistent and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2001;12:737-742. (Pubitemid 32607249)
96. Pikkarainen S, Tokola H, Kerkela R, Ilves M, Makinen M, Orzechowski HD et al. Inverse regulation of preproendothelin-1 and endothelin-converting enzyme-1beta genes in cardiac cells by mechanical load. Am J Physiol Regul Integr Comp Physiol 2006;290:R1639-R1645. (Pubitemid 43830830)
97. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrialventricular remodeling differences. Circulation 2008;117:1630-1641. (Pubitemid 351482606)
98. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-215.
99. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 1997;96:3053-3062. (Pubitemid 27500108)
100. Wozakowska-Kaplon B, Opolski G. Atrial natriuretic peptide level after cardioversion of chronic atrial fibrillation. Int J Cardiol 2002;83:159-165. (Pubitemid 34451081)
101. Van den Berg MP, Tjeerdsma G, De Kam PJ, Boomsma F, Crijns HJ, Van Veldhuisen DJ. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. Eur J Heart Fail 2002;4:255-262.
102. Silvet H, Young-Xu Y, Walleigh D, Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003;92:1124-1127. (Pubitemid 37329544)
103. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-1262.
104. Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van den Berg MP, Driessen C et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:827-835.
105. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-142. (Pubitemid 46916959)
106. Gardner DG, Newman ED, Nakamura KK, Nguyen KP. Endothelin increases the synthesis and secretion of atrial natriuretic peptide in neonatal rat cardiocytes. Am J Physiol 1991;261:E177-E182.
107. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010;7:438-444.
108. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16:470-474.
109. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-2319. (Pubitemid 39407332)
110. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74:75-84. (Pubitemid 46366949)
111. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104:174-180. (Pubitemid 32655834)
112. Reil JC, Hohl M, Oberhofer M, Kazakov A, Kaestner L, Mueller P et al. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovasc Res 2010;87:485-493.
113. Chen MC, Chang JP, Liu WH, Yang CH, Chen CJ, Fang CY et al. Increased serum oxidative stress in patients with severe mitral regurgitation: a new finding and potential mechanism for atrial enlargement. Clin Biochem 2009;42:943-948.
114. Li Y, Sheng L, Li W, Liu W, Gong Y, Xue H et al. Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs. Biochem Biophys Res Commun 2009;381:198-203.
115. Hoit BD. Matrix metalloproteinases and atrial structural remodeling. J Am Coll Cardiol 2003;42:345-347. (Pubitemid 36851428)
116. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004;43:818-825. (Pubitemid 38296482)
117. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 2008;52:211-215. (Pubitemid 351915782)
118. Kato K, Fujimaki T, Yoshida T, Oguri M, Yajima K, Hibino T et al. Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation. Europace 2009;11:332-337.
119. Wang TL, Yang YH, Chang H, Hung CR. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol 2004;37:785-794. (Pubitemid 39194570)
120. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10-24.
121. Goette A, Arndt M, Rocken C, Staack T, Bechtloff R, Reinhold D et al. Calpains and cytokines in fibrillating human atria. Am J Physiol Heart Circ Physiol 2002;283: H264-H272. (Pubitemid 34705348)
122. Ruwhof C, van Wamel AE, Egas JM, van der Laarse A. Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. Mol Cell Biochem 2000;208:89-98. (Pubitemid 30451459)
123. Verheule S, Sato T, Everett T, Engle SK, Otten D, Rubart-von der Lohe M et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465. (Pubitemid 38780318)
124. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res 2001;51: 637-646. (Pubitemid 32800706)
125. Vitadello M, Ausma J, Borgers M, Gambino A, Casarotto DC, Gorza L. Increased myocardial GRP94 amounts during sustained atrial fibrillation: a protective response? Circulation 2001;103:2201-2206.
126. Yang M, Tan H, Cheng L, He M, Wei Q, Tanguay RM et al. Expression of heat shock proteins in myocardium of patients with atrial fibrillation. Cell Stress Chaperones 2007; 12:142-150. (Pubitemid 350224163)
127. Brundel BJ, Henning RH, Ke L, Van Gelder IC, Crijns HJ, Kampinga HH. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006;41:555-562. (Pubitemid 44344288)
128. Schafler AE, Kirmanoglou K, Balbach J, Pecher P, Hannekum A, Schumacher B. The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res Cardiol 2002;97:258-261. (Pubitemid 34464160)
129. Brundel BJ, Shiroshita-Takeshita A, Qi X, Yeh YH, Chartier D, Van Gelder IC et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006;99:1394-1402. (Pubitemid 44949675)
130. Sakabe M, Shiroshita-Takeshita A, Maguy A, Brundel BJ, Fujiki A, Inoue H et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 2008;78:63-70. (Pubitemid 351430968)
131. Zhang X, Chen S, Yoo S, Chakrabarti S, Zhang T, Ke T et al. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell 2008;135:1017-1027.
132. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 1988;85:339-343.
133. Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63:236-244. (Pubitemid 38900838)
134. Ellinghaus P, Scheubel RJ, Dobrev D, Ravens U, Holtz J, Huetter J et al. Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. J Thorac Cardiovasc Surg 2005;129:1383-1390. (Pubitemid 40804859)
135. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009;30:2327-2336.